Exact Sciences Reports Strong Q2 Revenue Growth, Stock Falls 15%

Exact Sciences reported strong second-quarter 2025 earnings, surpassing analyst expectations with revenues of $811 million, a 16% year-over-year increase, and non-GAAP earnings per share of $0.22, significantly better than the expected loss. The company raised its full-year 2025 guidance for revenue and adjusted EBITDA, driven by robust adoption of new cancer tests, cost controls, and strategic progress. Exact Sciences focuses on early cancer detection through non-invasive screening and diagnostic tests, including its flagship Cologuard and precision oncology tests like Oncotype DX. Recent product launches such as Cologuard Plus and Oncodetect are critical to growth, supported by expanded commercial reach and partnerships with healthcare providers. Despite the positive results, the stock has underperformed the S&P 500 this year, losing about 15.7%, raising questions about future performance and investor sentiment. Management highlighted ongoing innovation, market expansion, and operational improvements as key drivers for sustained momentum and long-term growth.